bio techne brand recombinant human cd74 Search Results


93
R&D Systems recombinant human cd74
Fig. 3 In vivo stability of <t>anti-CD74-Phos-Bud.</t> To assess the stability of anti-CD74-Phos Bud in mice, the levels of antibody was determined by total antibody immunoassay (Total IA) and levels of intact ADC was determined by ADC specific immunoassay (ADC IA) on plasma samples from human CD74+ transgenic (Tg) mice IV dosed with 30 mg/kg (a), 10 mg/kg (b) and 3 mg/kg (c). Data plotted are mean from two mice per time point. Error bars correspond to the range. Error bars smaller than the symbol are not visible
Recombinant Human Cd74, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+brand+recombinant+human+cd74/10__1186_slash_s41120___018___0026___0-58-23-26?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant human cd74 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 3 In vivo stability of anti-CD74-Phos-Bud. To assess the stability of anti-CD74-Phos Bud in mice, the levels of antibody was determined by total antibody immunoassay (Total IA) and levels of intact ADC was determined by ADC specific immunoassay (ADC IA) on plasma samples from human CD74+ transgenic (Tg) mice IV dosed with 30 mg/kg (a), 10 mg/kg (b) and 3 mg/kg (c). Data plotted are mean from two mice per time point. Error bars correspond to the range. Error bars smaller than the symbol are not visible

Journal: AAPS Open

Article Title: Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection

doi: 10.1186/s41120-018-0026-0

Figure Lengend Snippet: Fig. 3 In vivo stability of anti-CD74-Phos-Bud. To assess the stability of anti-CD74-Phos Bud in mice, the levels of antibody was determined by total antibody immunoassay (Total IA) and levels of intact ADC was determined by ADC specific immunoassay (ADC IA) on plasma samples from human CD74+ transgenic (Tg) mice IV dosed with 30 mg/kg (a), 10 mg/kg (b) and 3 mg/kg (c). Data plotted are mean from two mice per time point. Error bars correspond to the range. Error bars smaller than the symbol are not visible

Article Snippet: For total anti-CD74 immunoassay (Total IA), measuring anti-CD74 antibody still capable of binding the target regardless of the presence or absence of payload, recombinant human CD74 (R&D System) was plated on MSD MA6000 96-Small Spot plate as a target capture and mouse anti-human IgG-SULTO-TAG (SouthernBiotech, Birmingham, AL) was used as detection reagent.

Techniques: In Vivo, Clinical Proteomics, Transgenic Assay

Fig. 4 Anti-CD74-Phos-Bud-interacting proteins in C57BL/6 J plasma. To determine any off-target protein binding, Anti-CD74-Phos-Bud was incubated in C57BL/6 J mouse plasma for 14 days at 37 °C and retrieved by pull-down. Pulled-down products were digested with trypsin and analyzed by LC-MS/MS for peptide mapping. Data represent the results of a single incubation at each time point

Journal: AAPS Open

Article Title: Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection

doi: 10.1186/s41120-018-0026-0

Figure Lengend Snippet: Fig. 4 Anti-CD74-Phos-Bud-interacting proteins in C57BL/6 J plasma. To determine any off-target protein binding, Anti-CD74-Phos-Bud was incubated in C57BL/6 J mouse plasma for 14 days at 37 °C and retrieved by pull-down. Pulled-down products were digested with trypsin and analyzed by LC-MS/MS for peptide mapping. Data represent the results of a single incubation at each time point

Article Snippet: For total anti-CD74 immunoassay (Total IA), measuring anti-CD74 antibody still capable of binding the target regardless of the presence or absence of payload, recombinant human CD74 (R&D System) was plated on MSD MA6000 96-Small Spot plate as a target capture and mouse anti-human IgG-SULTO-TAG (SouthernBiotech, Birmingham, AL) was used as detection reagent.

Techniques: Clinical Proteomics, Protein Binding, Incubation, Liquid Chromatography with Mass Spectroscopy

Fig. 6 Tissue distribution of anti-CD74–011 and anti-CD74-Phos-Bud. Microgram equivalent per gram concentration of antibodies in spleen (a) and liver (b) of WT or human CD74+ transgenic (Tg) mice were determined by fluorescence emission-linked assay at multiple time points over 2 days after 5 mg/kg IV dosing. An additional 15 min time-point was collected for anti-CD74-Phos-Bud in Tg mice. Data plotted are mean from two mice per time point. Error bars correspond to the range. Error bars smaller than the symbol are not plotted

Journal: AAPS Open

Article Title: Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection

doi: 10.1186/s41120-018-0026-0

Figure Lengend Snippet: Fig. 6 Tissue distribution of anti-CD74–011 and anti-CD74-Phos-Bud. Microgram equivalent per gram concentration of antibodies in spleen (a) and liver (b) of WT or human CD74+ transgenic (Tg) mice were determined by fluorescence emission-linked assay at multiple time points over 2 days after 5 mg/kg IV dosing. An additional 15 min time-point was collected for anti-CD74-Phos-Bud in Tg mice. Data plotted are mean from two mice per time point. Error bars correspond to the range. Error bars smaller than the symbol are not plotted

Article Snippet: For total anti-CD74 immunoassay (Total IA), measuring anti-CD74 antibody still capable of binding the target regardless of the presence or absence of payload, recombinant human CD74 (R&D System) was plated on MSD MA6000 96-Small Spot plate as a target capture and mouse anti-human IgG-SULTO-TAG (SouthernBiotech, Birmingham, AL) was used as detection reagent.

Techniques: Concentration Assay, Transgenic Assay, Fluorescence